Clinical Trial Update: A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer [Phase 1]

View source ↗

Summary

A Phase I trial evaluating XZP-3621 in Chinese patients with ALK- or ROS1-rearranged non-small cell lung cancer has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• XZP-3621

Snippet

Sponsor: Xuanzhu Biopharmaceutical Co., Ltd. | Conditions: ROS1 Rearrangement Non-small Cell Lung Cancer, ALK Rearrangement Non-small Cell Lung Cancer | Phase 1 | Status: COMPLETED